Camp4 Therapeutics Q1 Net Loss $18.3M; Revenue $1.29M
Camp4 Therapeutics reported an increased net loss for Q1 2026, reaching $18.3 million, compared to $12.4 million in Q1 2025. Research and collaboration revenue grew by 50.8% to $1.29 million. The company's cash and cash equivalents stood at $99.2 million as of March 31, 2026, and it expects to fund operations for at least 12 months. The derivative tranche liability increased by $6.19 million, contributing to the higher net loss, and two collaboration agreements with Fulcrum and BioMarin terminated.
Key Highlights
- Net loss increased to $18.3 million in Q1 2026 from $12.4 million in Q1 2025.
- Research and collaboration revenue rose 50.8% to $1.29 million in Q1 2026.
- Cash and cash equivalents were $99.2 million as of March 31, 2026.
- Net loss per share improved to $(0.32) from $(0.62) due to increased shares.
- Derivative tranche liability increased by $6.19 million to $50.95 million.
- Net cash used in operating activities decreased to $11.0 million from $14.3 million.
- Fulcrum and BioMarin collaboration agreements terminated.
Price Impact
More from CAMP
Camp4 Therapeutics Amends 2024 Equity Plan, Adopts 2026 Inducement Plan
CAMP4 CMP-002 Preclinical Data Improves Seizures in SYNGAP1 Disorder
Camp4 Therapeutics' CMP-002 Shows Significant Seizure Improvement in Preclinical Study